Why Amgen Is Buying Onyx for $10.4B

Aug. 26 (Bloomberg) -- Amgen agreed to buy Onyx Pharmaceuticals in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Where Are the Wages?: What'd You Miss? (Full Show 10/02)
35:56 - Full episode of "What'd You Miss?" Guests: Michelle Meyer, BofA Merrill Lynch's deputy head of U.S. economics, and Tom Lee, Fundstrat Global Advisors' head of research. (Source: Bloomberg)
  • Apple Patent Would Put a Ring on It
  • Sprint Plans to Cut Costs by Up to $2.5 Billion
  • Ben Lerer's Vision for the Future of Thrillist